O	0	6	Effect
O	7	9	of
B-intervention	10	22	mammographic
I-intervention	23	32	screening
O	33	37	from
O	38	41	age
O	42	44	40
O	45	50	years
O	51	53	on
O	54	60	breast
O	61	67	cancer
O	68	77	mortality
O	78	79	(
O	79	81	UK
O	82	85	Age
O	86	91	trial
O	91	92	)
O	92	93	:
O	94	99	final
O	100	107	results
O	108	110	of
O	111	112	a
O	113	123	randomised
O	123	124	,
O	125	135	controlled
O	136	141	trial
O	141	142	.

O	143	146	The
O	147	158	appropriate
O	159	162	age
O	163	168	range
O	169	172	for
O	173	179	breast
O	180	186	cancer
O	187	196	screening
O	197	204	remains
O	205	206	a
O	207	213	matter
O	214	216	of
O	217	223	debate
O	223	224	.

O	225	227	We
O	228	233	aimed
O	234	236	to
O	237	245	estimate
O	246	249	the
O	250	256	effect
O	257	259	of
O	260	272	mammographic
O	273	282	screening
O	283	285	at
O	286	290	ages
O	291	293	40
O	293	294	-
O	294	296	48
O	297	302	years
O	303	305	on
O	306	312	breast
O	313	319	cancer
O	320	329	mortality
O	329	330	.

O	331	333	We
O	334	337	did
O	338	339	a
O	340	350	randomised
O	350	351	,
O	352	362	controlled
O	363	368	trial
O	369	378	involving
O	379	381	23
O	382	388	breast
O	389	398	screening
O	399	404	units
O	405	411	across
B-location	412	417	Great
I-location	418	425	Britain
O	425	426	.

O	427	429	We
O	430	438	randomly
O	439	447	assigned
O	448	453	women
O	454	458	aged
B-age	459	461	39
I-age	461	462	-
I-age	462	464	41
I-age	465	470	years
O	470	471	,
O	472	477	using
O	478	488	individual
O	489	502	randomisation
O	502	503	,
O	504	514	stratified
O	515	517	by
O	518	525	general
O	526	534	practice
O	534	535	,
O	536	538	in
O	539	540	a
O	541	542	1
O	542	543	:
O	543	544	2
O	545	550	ratio
O	550	551	,
O	552	554	to
O	555	561	yearly
O	562	574	mammographic
O	575	584	screening
O	585	589	from
O	590	593	the
O	594	598	year
O	599	601	of
O	602	611	inclusion
O	612	614	in
O	615	618	the
O	619	624	trial
O	625	627	up
O	628	630	to
O	631	634	and
O	635	644	including
O	645	648	the
O	649	657	calendar
O	658	662	year
O	663	667	that
O	668	672	they
O	673	680	reached
O	681	684	age
O	685	687	48
O	688	693	years
O	694	695	(
O	695	707	intervention
O	708	713	group
O	713	714	)
O	714	715	,
O	716	718	or
O	719	721	to
B-control	722	730	standard
I-control	731	735	care
I-control	736	738	of
I-control	739	741	no
I-control	742	751	screening
O	752	757	until
O	758	761	the
O	762	772	invitation
O	773	775	to
O	776	781	their
O	782	787	first
O	788	796	National
O	797	803	Health
O	804	811	Service
O	812	818	Breast
O	819	828	Screening
O	829	838	Programme
O	839	840	(
O	840	846	NHSBSP
O	846	847	)
O	848	854	screen
O	855	857	at
O	858	871	approximately
O	872	875	age
O	876	878	50
O	879	884	years
O	885	886	(
O	886	893	control
O	894	899	group
O	899	900	)
O	900	901	.

O	902	907	Women
O	908	910	in
O	911	914	the
O	915	927	intervention
O	928	933	group
O	934	938	were
O	939	948	recruited
O	949	951	by
O	952	958	postal
O	959	969	invitation
O	969	970	.

O	971	976	Women
O	977	979	in
O	980	983	the
O	984	991	control
O	992	997	group
O	998	1002	were
O	1003	1010	unaware
O	1011	1013	of
O	1014	1017	the
O	1018	1023	study
O	1023	1024	.

O	1025	1028	The
O	1029	1036	primary
O	1037	1045	endpoint
O	1046	1049	was
B-outcome-Measure	1050	1059	mortality
I-outcome-Measure	1060	1064	from
I-outcome-Measure	1065	1071	breast
I-outcome-Measure	1072	1079	cancers
O	1080	1081	(
O	1081	1085	with
O	1086	1092	breast
O	1093	1099	cancer
O	1100	1105	coded
O	1106	1108	as
O	1109	1112	the
O	1113	1123	underlying
O	1124	1129	cause
O	1130	1132	of
O	1133	1138	death
O	1138	1139	)
O	1140	1149	diagnosed
O	1150	1156	during
O	1157	1160	the
O	1161	1173	intervention
O	1174	1180	period
O	1180	1181	,
O	1182	1188	before
O	1189	1192	the
O	1193	1204	participant
O	1204	1205	'
O	1205	1206	s
O	1207	1212	first
O	1213	1219	NHSBSP
O	1220	1226	screen
O	1226	1227	.

O	1228	1230	To
O	1231	1236	study
O	1237	1240	the
O	1241	1247	timing
O	1248	1250	of
O	1251	1254	the
O	1255	1264	mortality
O	1265	1271	effect
O	1271	1272	,
O	1273	1275	we
O	1276	1284	analysed
O	1285	1288	the
O	1289	1296	results
O	1297	1299	in
O	1300	1309	different
O	1310	1316	follow
O	1316	1317	-
O	1317	1319	up
O	1320	1327	periods
O	1327	1328	.

O	1329	1334	Women
O	1335	1339	were
O	1340	1348	included
O	1349	1351	in
O	1352	1355	the
O	1356	1363	primary
O	1364	1374	comparison
O	1375	1385	regardless
O	1386	1388	of
O	1389	1399	compliance
O	1400	1404	with
O	1405	1418	randomisation
O	1419	1425	status
O	1426	1427	(
O	1427	1436	intention
O	1436	1437	-
O	1437	1439	to
O	1439	1440	-
O	1440	1445	treat
O	1446	1454	analysis
O	1454	1455	)
O	1455	1456	.

O	1457	1461	This
O	1462	1469	Article
O	1470	1477	reports
O	1478	1480	on
O	1481	1485	long
O	1485	1486	-
O	1486	1490	term
O	1491	1497	follow
O	1497	1498	-
O	1498	1500	up
O	1501	1509	analysis
O	1509	1510	.

O	1511	1514	The
O	1515	1520	trial
O	1521	1523	is
O	1524	1534	registered
O	1535	1539	with
O	1540	1543	the
O	1544	1550	ISRCTN
O	1551	1559	registry
O	1559	1560	,
O	1561	1575	ISRCTN24647151
O	1575	1576	.

B-total-participants	1577	1580	160
I-total-participants	1581	1584	921
O	1585	1590	women
O	1591	1595	were
O	1596	1605	recruited
O	1606	1613	between
O	1614	1617	Oct
O	1618	1620	14
O	1620	1621	,
O	1622	1626	1990
O	1626	1627	,
O	1628	1631	and
O	1632	1636	Sept
O	1637	1639	24
O	1639	1640	,
O	1641	1645	1997
O	1645	1646	.

B-intervention-participants	1647	1649	53
I-intervention-participants	1650	1653	883
O	1654	1659	women
O	1660	1661	(
O	1661	1663	33
O	1663	1664	·
O	1664	1665	5
O	1665	1666	%
O	1666	1667	)
O	1668	1672	were
O	1673	1681	randomly
O	1682	1690	assigned
O	1691	1693	to
O	1694	1697	the
O	1698	1710	intervention
O	1711	1716	group
O	1717	1720	and
B-control-participants	1721	1724	106
I-control-participants	1725	1728	953
O	1729	1730	(
O	1730	1732	66
O	1732	1733	·
O	1733	1734	5
O	1734	1735	%
O	1735	1736	)
O	1737	1739	to
O	1740	1743	the
O	1744	1751	control
O	1752	1757	group
O	1757	1758	.

O	1759	1766	Between
O	1767	1780	randomisation
O	1781	1784	and
O	1785	1788	Feb
O	1789	1791	28
O	1791	1792	,
O	1793	1797	2017
O	1797	1798	,
O	1799	1804	women
O	1805	1809	were
O	1810	1818	followed
O	1819	1821	up
O	1822	1825	for
O	1826	1827	a
O	1828	1834	median
O	1835	1837	of
O	1838	1840	22
O	1840	1841	·
O	1841	1842	8
O	1843	1848	years
O	1849	1850	(
O	1850	1853	IQR
O	1854	1856	21
O	1856	1857	·
O	1857	1858	8
O	1858	1859	-
O	1859	1861	24
O	1861	1862	·
O	1862	1863	0
O	1863	1864	)
O	1864	1865	.

O	1866	1868	We
O	1869	1877	observed
O	1878	1879	a
O	1880	1891	significant
O	1892	1901	reduction
O	1902	1904	in
O	1905	1911	breast
O	1912	1918	cancer
O	1919	1928	mortality
B-outcome	1929	1931	at
I-outcome	1932	1934	10
I-outcome	1935	1940	years
I-outcome	1941	1943	of
I-outcome	1944	1950	follow
I-outcome	1950	1951	-
I-outcome	1951	1953	up
O	1953	1954	,
O	1955	1959	with
B-iv-bin-abs	1960	1962	83
B-outcome	1963	1969	breast
I-outcome	1970	1976	cancer
I-outcome	1977	1983	deaths
O	1984	1986	in
O	1987	1990	the
O	1991	2003	intervention
O	2004	2009	group
O	2010	2016	versus
B-cv-bin-percent	2017	2020	219
O	2021	2023	in
O	2024	2027	the
O	2028	2035	control
O	2036	2041	group
O	2042	2043	(
O	2043	2051	relative
O	2052	2056	rate
O	2057	2058	[
O	2058	2060	RR
O	2060	2061	]
O	2062	2063	0
O	2063	2064	·
O	2064	2066	75
O	2067	2068	[
O	2068	2070	95
O	2070	2071	%
O	2072	2074	CI
O	2075	2076	0
O	2076	2077	·
O	2077	2079	58
O	2079	2080	-
O	2080	2081	0
O	2081	2082	·
O	2082	2084	97
O	2084	2085	]
O	2085	2086	;
O	2087	2088	p
O	2088	2089	=
O	2089	2090	0
O	2090	2091	·
O	2091	2094	029
O	2094	2095	)
O	2095	2096	.

O	2097	2099	No
O	2100	2111	significant
O	2112	2121	reduction
O	2122	2125	was
O	2126	2134	observed
O	2135	2145	thereafter
O	2145	2146	,
O	2147	2151	with
B-iv-bin-abs	2152	2155	126
B-outcome	2156	2162	deaths
O	2163	2169	versus
B-cv-bin-abs	2170	2173	255
O	2174	2180	deaths
O	2181	2190	occurring
B-outcome	2191	2196	after
I-outcome	2197	2201	more
I-outcome	2202	2206	than
I-outcome	2207	2209	10
I-outcome	2210	2215	years
I-outcome	2216	2218	of
I-outcome	2219	2225	follow
I-outcome	2225	2226	-
I-outcome	2226	2228	up
O	2229	2230	(
O	2230	2232	RR
O	2233	2234	0
O	2234	2235	·
O	2235	2237	98
O	2238	2239	[
O	2239	2240	0
O	2240	2241	·
O	2241	2243	79
O	2243	2244	-
O	2244	2245	1
O	2245	2246	·
O	2246	2248	22
O	2248	2249	]
O	2249	2250	;
O	2251	2252	p
O	2252	2253	=
O	2253	2254	0
O	2254	2255	·
O	2255	2257	86
O	2257	2258	)
O	2258	2259	.

O	2260	2266	Yearly
O	2267	2278	mammography
O	2279	2285	before
O	2286	2289	age
O	2290	2292	50
O	2293	2298	years
O	2298	2299	,
O	2300	2310	commencing
O	2311	2313	at
O	2314	2317	age
O	2318	2320	40
O	2321	2323	or
O	2324	2326	41
O	2327	2332	years
O	2332	2333	,
O	2334	2337	was
O	2338	2348	associated
O	2349	2353	with
O	2354	2355	a
O	2356	2364	relative
O	2365	2374	reduction
O	2375	2377	in
B-outcome	2378	2384	breast
I-outcome	2385	2391	cancer
I-outcome	2392	2401	mortality
O	2401	2402	,
O	2403	2408	which
O	2409	2412	was
O	2413	2423	attenuated
O	2424	2429	after
O	2430	2432	10
O	2433	2438	years
O	2438	2439	,
O	2440	2448	although
O	2449	2452	the
O	2453	2461	absolute
O	2462	2471	reduction
O	2472	2480	remained
O	2481	2489	constant
O	2489	2490	.

O	2491	2499	Reducing
O	2500	2503	the
O	2504	2509	lower
O	2510	2513	age
O	2514	2519	limit
O	2520	2523	for
O	2524	2533	screening
O	2534	2538	from
O	2539	2541	50
O	2542	2544	to
O	2545	2547	40
O	2548	2553	years
O	2554	2559	could
O	2560	2571	potentially
O	2572	2578	reduce
O	2579	2585	breast
O	2586	2592	cancer
O	2593	2602	mortality
O	2602	2603	.

O	2604	2612	National
O	2613	2622	Institute
O	2623	2626	for
O	2627	2633	Health
O	2634	2642	Research
O	2643	2649	Health
O	2650	2660	Technology
O	2661	2671	Assessment
O	2672	2681	programme
O	2681	2682	.
